US Oncology Launches Oncology-Specific EHR

Publication
Article
OncologyONCOLOGY Vol 23 No 8
Volume 23
Issue 8

US Oncology, Inc, announced the launch of iKnowMed-an oncology-specific electronic health record (EHR) system designed by oncologists for oncologists-to the open market.

US Oncology, Inc, announced the launch of iKnowMed-an oncology-specific electronic health record (EHR) system designed by oncologists for oncologists-to the open market. Features of iKnowMed include oncology-specific terminology, decision support, outcomes reporting, and imaging reports.

Articles in this issue
Resolving Confusion: The New Realities of Mantle Cell Lymphoma
Something Old, Something New: Options for Treating Relapsed Mantle Cell Lymphoma
Supraclavicular Extraskeletal Myxoid Chondrosarcoma Presenting With a Sensorimotor Polyneuropathy Associated With Anti-Hu Antibodies
Supraclavicular Extraskeletal Myxoid Chondrosarcoma Presenting With a Sensorimotor Polyneuropathy Associated With Anti-Hu Antibodies
Reishi Mushroom
Reishi Mushroom
Unraveling the Mystery of a Supraclavicular Mass
Management of Relapsed Mantle Cell Lymphoma: Still a Treatment Challenge
Sunitinib Improves Progression-Free Survival in Patients With Advanced Pancreatic Islet Cell Tumors
Phase III Trial Initiated for BLP25 Liposome Vaccine in Breast Cancer Patients
US Oncology Launches Oncology-Specific EHR
Effective Local Therapy and Long-Term Survival in Breast Cancer
Local Therapy Matters
Deemphasize Dogma: Consider the Local Control–Overall Survival Link
Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura
The Road to Romiplostim Approval and Beyond
The REMS Publication Paradox
Recent Videos
Related Content
3 Things You Should Know About Hemolytic Anemias

3 Things You Should Know About Hemolytic Anemias

Catherine M. Broome, MD;Sigbjørn Berentsen, MD, PhD;Caroline Piatek, MD;Ilene Ceil Weitz, MD
December 20th 2024
Article

Hemolytic anemias are a collection of rare but severe diseases including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

General Lifestyle Recommendations for Receiving Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
December 10th 2024
Article

Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Efficacy and Safety of Zolbetuximab in Gastric Cancer

Aiman Waheed, MBBS;Muhammad Numan Saleem, MBBS;Yash Shah, MD;Muhammad Hamza Gul, MBBS, MD;Helai Hussaini, MD;Abdul Baseer Wardak, MBBS
December 6th 2024
Article

Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials

Clayton K. Oakley, DO, MS, MA;Amulya Yellala, MD;Sunil Tulpule, MD;Robin High, MA;Apar Kishor Ganti, MD;Alissa S. Marr, MD
December 5th 2024
Article

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.